Product
Enobosarm
Aliases
VERU-024
3 clinical trials
9 indications
Indication
Breast CancerIndication
Muscle AtrophyIndication
ObesityIndication
Androgen Receptor PositiveIndication
Estrogen Receptor NegativeIndication
HER2/Neu NegativeIndication
Triple-Negative Breast CarcinomaIndication
Progesterone Receptor NegativeIndication
Breast cancerClinical trial
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 InhibitorStatus: Terminated, Estimated PCD: 2024-01-09
Clinical trial
A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight ManagementStatus: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)Status: Completed, Estimated PCD: 2020-10-28